Literature DB >> 27580575

Clinical and Diagnostic Aspects of Brucellosis and Antimicrobial Susceptibility of Brucella Isolates in Hamedan, Iran.

Fatemeh Torkaman Asadi1,2, Seyyed Hamid Hashemi1,3, Mohammad Yousef Alikhani1, Abbas Moghimbeigi1, Zahra Naseri2.   

Abstract

Current drug regimens for brucellosis are associated with relatively high rates of therapeutic failure or relapse. Reduced antimicrobial susceptibility of Brucella spp. has been proposed recently as a potential cause of therapeutic failure. The aim of this study was to evaluate the antibiotic resistance pattern of Brucella melitensis clinical isolates by E-test method in Hamadan, west of Iran. In a 15-month period, all patients with suspected brucellosis were enrolled. Blood specimens were collected for diagnosis of brucellosis by BACTEC system and serological tests. Antimicrobial susceptibility of clinical isolates to 7 antibiotics was assessed by the E-test method. One hundred forty-nine patients with brucellosis were evaluated. 38.3% of cultures of clinical samples were positive for BACTEC system, of which 91.2% were associated with a positive serological test result. No significant associations were found between serology and the culture method. All Brucella isolates were susceptible to doxycycline, streptomycin, gentamicin, ciprofloxacin, and moxifloxacin. However, decreased sensitivity to rifampin and trimethoprim-sulfamethoxazole was found in 35.1% and 3.5% of isolates, respectively. Because of the high rates of intermediate sensitivity to rifampin among Brucella isolates, this drug should be prescribed with caution. We recommend restricting the use of rifampin for treatment of brucellosis except as an alternative drug for special situations.

Entities:  

Keywords:  E-test; brucellosis; drug resistance

Mesh:

Substances:

Year:  2016        PMID: 27580575     DOI: 10.7883/yoken.JJID.2016.133

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  7 in total

1.  Identification, Genotyping and Antimicrobial Susceptibility Testing of Brucella spp. Isolated from Livestock in Egypt.

Authors:  Aman Ullah Khan; Waleed S Shell; Falk Melzer; Ashraf E Sayour; Eman Shawkat Ramadan; Mandy C Elschner; Amira A Moawad; Uwe Roesler; Heinrich Neubauer; Hosny El-Adawy
Journal:  Microorganisms       Date:  2019-11-22

2.  Epidemiologically characteristics of human brucellosis and antimicrobial susceptibility pattern of Brucella melitensis in Hinggan League of the Inner Mongolia Autonomous Region, China.

Authors:  Hai-Tao Yuan; Cheng-Ling Wang; Li-Na Liu; Dan Wang; Dan Li; Zhen-Jun Li; Zhi-Guo Liu
Journal:  Infect Dis Poverty       Date:  2020-06-29       Impact factor: 4.520

3.  Proteomics-based screening and antibiotic resistance assessment of clinical and sub-clinical Brucella species: An evolution of brucellosis infection control.

Authors:  Ayman Elbehiry; Musaad Aldubaib; Osamah Al Rugaie; Eman Marzouk; Marwan Abaalkhail; Ihab Moussa; Mohamed H El-Husseiny; Adil Abalkhail; Mohammed Rawway
Journal:  PLoS One       Date:  2022-01-13       Impact factor: 3.240

4.  Trends of human brucellosis in Central Iran (2010-2018).

Authors:  Mohammad-Sadegh Khalilian; Javad Ramazanpour; Sayed Mohsen Hosseini; Sina Narrei; Mehrdad Zeinalian
Journal:  J Res Med Sci       Date:  2021-08-30       Impact factor: 1.852

5.  Whole-genome sequencing and antimicrobial resistance in Brucella melitensis from a Norwegian perspective.

Authors:  Tone B Johansen; Lonneke Scheffer; Veronica K Jensen; Jon Bohlin; Siri L Feruglio
Journal:  Sci Rep       Date:  2018-06-04       Impact factor: 4.379

6.  Investigation of the Sensitivity and Specificity of Laboratory Tests Used in Differential Diagnosis of Childhood Brucellosis.

Authors:  Halil Kazanasmaz; Süleyman Geter
Journal:  Cureus       Date:  2020-01-23

7.  Antimicrobial susceptibility of Brucella spp. isolated from Iranian patients during 2016 to 2018.

Authors:  Saeed Alamian; Maryam Dadar; Afshar Etemadi; Davoud Afshar; Mohammad Mehdi Alamian
Journal:  Iran J Microbiol       Date:  2019-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.